KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Leases (2021 - 2025)

AbCellera Biologics' Leases history spans 5 years, with the latest figure at $137.9 million for Q3 2025.

  • For the quarter ending Q3 2025, Leases rose 101.87% year-over-year to $137.9 million, compared with a TTM value of $137.9 million through Sep 2025, up 101.87%, and an annual FY2024 reading of $66.6 million, down 8.88% over the prior year.
  • Leases for Q3 2025 was $137.9 million at AbCellera Biologics, up from $136.9 million in the prior quarter.
  • The five-year high for Leases was $137.9 million in Q3 2025, with the low at $6.6 million in Q1 2022.
  • Average Leases over 5 years is $65.6 million, with a median of $68.5 million recorded in 2024.
  • Year-over-year, Leases surged 632.47% in 2023 and then decreased 26.17% in 2025.
  • Tracing ABCL's Leases over 5 years: stood at $19.8 million in 2021, then skyrocketed by 308.27% to $80.8 million in 2022, then decreased by 9.52% to $73.1 million in 2023, then decreased by 8.88% to $66.6 million in 2024, then surged by 106.93% to $137.9 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Leases are $137.9 million (Q3 2025), $136.9 million (Q2 2025), and $68.7 million (Q1 2025).